ArticlePLoS medicine2019
Advances in clinical trial design for development of new TB treatments: A call for innovation.
Article in PLoS medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts.BMC infectious diseases · 2022Trial
- Improving the efficiency of drug resistant tuberculosis treatment trials: a time-to-event alternative marker for bacteriological response and adaptive minimization for randomization.BMC medical research methodology · 2025Article
- Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes.Annals of the American Thoracic Society · 2023Article
- A comparison of clinical development pathways to advance tuberculosis regimen development.BMC infectious diseases · 2022Article
- Screening Repurposed Antiviral Small Molecules as Antimycobacterial Compounds by a Lux-Based phoP Promoter-Reporter Platform.Antibiotics (Basel, Switzerland) · 2022Article
- vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding.BMC bioinformatics · 2022Article
- The pipeline of new molecules and regimens against drug-resistant tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Review
- Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.American journal of respiratory and critical care medicine · 2021Article
- The potential use of digital health technologies in the African context: a systematic review of evidence from Ethiopia.NPJ digital medicine · 2021Review
- Is deployement of diagnostic test alone enough? Comprehensive package of interventions to strengthen TB laboratory network: three years of experience in Burkina Faso.BMC infectious diseases · 2021Article
- Advances in clinical trial design: Weaving tomorrow's TB treatments.PLoS medicine · 2020Review
- The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials.PLoS medicine · 2019Article
- Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.PLoS medicine · 2019Review
- Article
- Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness.PLoS medicine · 2019Article
- Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.PLoS medicine · 2019Article
- Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.PLoS medicine · 2019Review
- Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.PLoS medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Christian Lienhardt and Payam Nahid launch the Collection on Advances in Clinical Trial Design for Development of New Tuberculosis Treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.